Creo Medical Directors Boost Shareholdings Amid Fundraising

Leading UK medical device company Creo Medical Group has announced that its directors have increased their shareholdings in the company.

The move comes as Creo prepares to raise new funds to support its continued growth.

The directors who have increased their shareholdings are CEO Craig Gulliford, CFO Steve Pearce, and Non-Executive Director William White. Gulliford has increased his stake in the company from 1.02% to 1.06%, Pearce has increased his stake from 0.05% to 0.07%, and White has increased his stake from 0.02% to 0.03%.

The share purchases were made on the open market at a price of 146 pence per share. Creo Medical's share price has risen by over 20% in the past year.

The directors' share purchases are a sign of their confidence in the company's future prospects. Creo Medical is a leading provider of minimally invasive surgical devices for the treatment of gastrointestinal diseases. The company's products are used in over 50 countries around the world.

Creo Medical is currently preparing to raise new funds to support its continued growth. The company is expected to announce the details of the fundraising in the coming weeks.

The fundraising will be used to support Creo Medical's expansion into new markets and to develop new products. The company is also planning to increase its production capacity.

Creo Medical is a well-positioned company with a strong track record of growth. The directors' share purchases are a vote of confidence in the company's future prospects.